[1]Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. Cancer statistics, 2014[J]. Ca A Cancer Journal for Clinicians, 2014, 62(1):10.
[2] Auriemma W S, Berger A C, Bar-Ad V, et al. Locally advanced pancreatic cancer.[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2005, 23(20):126-128.
[3] Sabater L, Muñoz E, Roselló S, et al. Borderline resectable pancreatic cancer. Challenges and controversies.[J]. Cancer Treatment Reviews, 2018.
[4] Lin Q J, Feng Y, Chen J, et al. Current status and progress of pancreatic cancer in China[J]. World Journal of Gastroenterology, 2015, 21(26):7988-8003.
[5] Krishnan S, Rana V, Janjan N A, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.[J]. Cancer, 2007, 110(1):47-55.
[6] Hammel P, Huguet F, van Laethem J L, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial [J]. Jama, 2016, 315(17):1844-1853.
[7] Nakamura A, Shibuya K, Matsuo Y, et al. Analysis of Dosimetric Parameters Associated With Acute Gastrointestinal Toxicity and Upper Gastrointestinal Bleeding in Locally Advanced Pancreatic Cancer Patients Treated With Gemcitabine-Based Concurrent Chemoradiotherapy This work was presented at the [J]. International Journal of Radiation Oncology Biology Physics, 2012, 84(2):369-75.
[8] Ben-Josef E, Schipper M, Francis I R, et al. A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer[J]. International Journal of Radiation Oncology Biology Physics, 2012, 84(5):1166-71.
[9] Dholakia A S, Chang D T, Goodman K A, et al. A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarcinoma.[J]. Practical Radiation Oncology, 2013, 3(2):S4-S5.
[10] Trakul N, Koong A C, Maxim P G, et al. Modern radiation therapy techniques for pancreatic cancer.[J]. Gastroenterol Clin North Am, 2012, 41(1):223-235.
[11] Akushevich I, Kravchenko J, Akushevich L, et al. Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy [J]. International Journal of Radiation Oncology Biology Physics, 2012, 82(2):508-518.
[12]Yovino S, Poppe M, Jabbour S, et al. Intensity-Modulated Radiation Therapy Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers [J]. International Journal of Radiation Oncology Biology Physics, 2011, 79(1):158-162.
[13 Goto Y, Nakamura A, Ashida R, et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer [J]. Radiation Oncology, 2018, 13(1):118.
[14] Colbert L E, Moningi S, Chadha A, et al. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC.[J]. Advances in Radiation Oncology, 2017, 2(3):403-415.
[15] Brown M W, Ning H, Arora B, et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma [J]. International Journal of Radiation Oncology Biology Physics, 2006, 65(1):274-283.
[16] Jones A O, Kleiman M T. Patient setup and verification for intensity-modulated radiation therapy (IMRT) [J]. Medical Dosimetry, 2003, 28(3):175-183.
[17] Dagoglu N, Callery M, Moser J, et al. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer[J]. J Cancer, 2016, 7(3):283-288.
[18] Hajj C, Goodman K A. Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers [J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2015, 33(16):1737.
[19] Kim S K, Wu C, Horowitz D P. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist [J]. Journal of Gastrointestinal Oncology, 2016, 7(3):479.
[20] Moningi S, Dholakia A S, Raman S P, et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience [J]. Annals of Surgical Oncology, 2015, 22(7):2352.
[21] Milano M T, Constine L S, Paul O. Normal tissue toxicity after small field hypofractionated stereotactic body radiation [J]. Radiation Oncology, 2008, 3(1):36.
[22] Lin J C, Jen Y M, Li M H, et al. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer [J]. European Journal of Gastroenterology & Hepatology, 2015, 27(3):259-64.
[23] Kumar R, Wild A T, Ziegler M A, et al. Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis [J]. Medical Dosimetry, 2013, 38(3):243-250.
[24] Antypas C, Pantelis E. Performance evaluation of a CyberKnife G4 image-guided robotic stereotactic radiosurgery system [J]. Physics in Medicine & Biology, 2008, 53(17):4697-4718.
[25]Qing S W, Ju X P, Cao Y S, et al. Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study [J]. Radiation Oncology, 2017, 12(1):6.
[26] Wen N, Li H, Song K, et al. Characteristics of a novel treatment system for linear accelerator-based stereotactic radiosurgery[J]. Journal of Applied Clinical Medical Physics, 2015, 16(4):5313.
[27] Yin F F, Zhu J, Yan H, et al. Dosimetric characteristics of Novalis shaped beam surgery unit [J]. Medical Physics, 2002, 29(8):1729-1738.
[28] Georg D, Knöös T, Mcclean B. Current status and future perspective of flattening filter free photon beams [J]. Medical Physics, 2011, 38(3):1280-1293.
[29] Chang Z, Wang Z, Wu Q J, et al. Dosimetric characteristics of novalis Tx system with high definition multileaf collimator.[J]. Medical Physics, 2008, 35(10):4460-4463.
[30]Goodman K A, Regine W F. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer [J]. International Journal of Radiation Oncology Biology Physics, 2012, 83(3):901-8.
[31] Regine W, Lowy AM, et al. RTOG 0848: A phase III trial evaluating both erlotinib and chemoradiation as adjuvant treatment for patients with resected head of pancreatic cancer. RTOG, 2010.
[32] Ling T C, Slater J M, Mifflin R, et al. Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848[J]. Journal of gastrointestinal oncology, 2015, 6(2):108.
[33] Stanley H, Benedict. Stereotactic body radiation therapy: The report of AAPM Task Group 101 [J], Phys Med.2010, 37(8).
[34] Feuvret L, Noël G, Mazeron J J, et al. Conformity index: a review [J]. International Journal of Radiation Oncology Biology Physics, 2006, 64(2):333.
[35] Kataria T, Sharma K, Subramani V, et al. Homogeneity Index: An objective tool for assessment of conformal radiation treatments [J]. Journal of Medical Physics, 2012, 37(4):207.
[36] Paddick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index [J]. Journal of Neurosurgery, 2006, 105 Suppl: 194-201.
[37] Niemierko, A. (1999) A Generalized Concept of Equivalent Uniform Dose (EUD). Medical Physics, 26, 1100.
[38]Gary Luxton, Paul J Keall and Christopher R King. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). Phys Med Biol, 2008;53:23.
[39] Li Y, Shi F, Tian Z, et al. SU-E-J-133: Evaluation of Inter- and Intra-Fractional Pancreas Tumor Residual Motions with Abdominal Compression[J]. Medical Physics, 2014, 41(6Part8):186-186.
[40] Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer.
[41] Fukada J, Kitago M, Sutani S, et al. Quantification of Interfraction and Intrafraction Pancreas Motion Using Pancreatic Stent[J]. International Journal of Radiation Oncology Biology Physics, 2015, 93(3):E178-E179.
[42] Scobie S, Adamson S, Malik J, et al. Intrafraction Prostate Motion during Radical Radiotherapy: Evaluation of Current Clinical Tolerance[J]. Clinical Oncology, 2015, 27(3):e5-e5.
[43] Minn A Y, Schellenberg D, Maxim P, et al. Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment[J]. American Journal of Clinical Oncology, 2009, 32(4):364.